Cinclus Pharma
Research Cinclus Pharma (CINPHA) on Bullrun: market cap SEK 614.30M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerCINPHA
- ExchangeST
- CountrySweden
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencySEK
- Market capSEK 614.30M
- Financial periodQ1 2026
- RevenueSEK 10.04M
- Net income-SEK 88.77M
- Free cash flow-SEK 95.67M
Valuation Snapshot
latest market cap is SEK 614.30M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | SEK 57.47M | -SEK 183.97M | -SEK 75.78M | n/a | -3.94 | SEK 487.25M | SEK 7.90M | SEK 369.39M |
| FY2024 | n/a | -SEK 168.03M | n/a | n/a | -4.54 | SEK 566.72M | SEK 299.00K | SEK 555.33M |
| FY2023 | n/a | -SEK 215.12M | n/a | n/a | -8.2 | SEK 87.97M | n/a | -SEK 76.80M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-24 | SEK 614.30M | n/a | n/a | n/a |
About Cinclus Pharma
Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Cinclus Pharma's market cap?
Cinclus Pharma's market capitalization is SEK 614.30M.
What does Cinclus Pharma do?
Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori. Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden.